Brad Swedlund
Papers
1
Total Citations
40
H-Index
1
About
Brad Swedlund is a translational researcher whose work centers on the molecular characterization of ovarian cancer, with a particular focus on homologous recombination deficiency (HRD) as a critical biomarker for targeted therapy. His major contribution lies in demonstrating how real-world, next-generation sequencing can reliably identify HRD in ovarian carcinoma, moving beyond controlled clinical trials to everyday diagnostic practice. In his landmark 2022 study, which has garnered 40 citations, Swedlund evaluated 514 ovarian tumor samples, analyzing BRCA1/BRCA2 alongside over 26,000 single-nucleotide polymorphisms to assess genomic instability. This work not only validated HRD testing in a routine clinical setting but also underscored its utility in guiding PARP inhibitor therapy for patients. By bridging the gap between genomic discovery and practical oncology, Swedlund’s research empowers clinicians to make more precise, personalized treatment decisions. His findings have become a touchstone for integrating HRD assessment into standard-of-care workflows, directly impacting how ovarian cancer patients are stratified for life-extending therapies.
Research Focus
Key Achievements
Top Papers
- 1